Boehringer Ingelheim has announced the initiation of a new Phase III clinical trial to evaluate one of its promising new late late-stage oncology compounds for the treatment of advanced ovarian cancer.
The LUME-Ovar-1 trial will investigate the novel oral anti-angiogenic agent BIBF 1120, as a first-line treatment in combination with standard chemotherapy compared to placebo in combination with standard chemotherapy.
BIBF 1120, which would be marketed under the name Vargatef, works by simultaneously inhibiting three receptors involved in providing the blood needed for tumours to grow and spread.
AGO study group international coordinating investigator of this trial Andreas du Bois said that anti-angiogenic compounds are one of the most promising new approaches in treating cancer.
"Ovarian cancer appears to be particularly sensitive to these novel agents, as suggested by early clinical trials," said du Bois.
The decision to progress to Phase III trials in ovarian cancer was based on previous study results, which showed the drug to be effective and well tolerated as a maintenance therapy for patients with relapsed ovarian cancer who had responded to prior chemotherapy.
LUME-Ovar 1 is an intergroup study conducted by an international consortium of study groups led by the AGO Study Group (Arbeitsgemeinschaft Gynaekologische Onkologie Study Group, Germany) and Boehringer Ingelheim.